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A protein that binds to the main apoprotein, apoA-I, of human high density lipoprotein (HDL) has been 
isolated from human placenta. Ligand blotting after SDS gel electrophoresis indicated that the 120 kDa 
protein in the absence of reducing agents binds apoA-I. If gel electrophoresis was performed under educing 
conditions two main bands, approx. 50 and 30 kDa that did not bind apoA-I, were evident. In an enzyme- 
linked immunosorbent assay the binding protein specifically bound apoA-I, delipidated or as HDL. ApoA- 
II, apo E and LDL did not compete with apoA-I for binding to this protein. 
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1. INTRODUCTION 
The concept that high density lipoproteins 
(HDL) have a protective role against development 
of coronary artery disease [1,2] has greatly 
stimulated the study of this lipoprotein class. HDL 
are initially secreted into circulation as precursor 
lipoproteins which are transformed intravascularly 
to spherical HDL [3]. This circulating HDL is a 
heterogeneous class of lipoproteins [4], in which 
the ratio of the two main apoproteins, apoA-I and 
apoA-II, varies among the subclasses [5]. Several 
studies have indicated that HDL are involved in 
the net movement of cholesterol out of cells [6] and 
in the delivery of cholesterol to hepatic and 
steroidogenic cells [7,8]. In cultured macrophages 
a receptor-mediated retroendocytosis pathway for 
HDL has been demonstrated [9,10]. Proteins that 
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bind HDL or HDL apoproteins have been partially 
purified from rat liver and kidney [11] and adrenal 
membranes [12]. It has also been demonstrated 
that placental cells display specific binding of HDL 
[13l. 
We recently reported that acid phosphatases 
avidly bind to the main high density lipoprotein 
apoprotein A-1 [14]. However, further studies in- 
dicate that apoA-I does not bind to the enzyme but 
to a protein that co-elutes with t e enzyme during 
affinity chromatography on L-(+)-tartrate. We 
now describe the isolation and partial characteriza- 
tion of this apoA-I-binding protein (apoA-I BP) 
from human placenta. 
2. MATERIALS AND METHODS 
2.1. Purification o f  human apoA-I-binding 
protein 
2.1.1. Ammonium sulphate precipitation 
Full-term human placenta (obtained from the 
Department of Gynaecology, University of 
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Helsinki) was homogenized in distilled water con- 
taining 1 ml/1 Tween 20 Atlas. After 12 h at 4°C 
the homogenate was centrifuged to remove cellular 
debris and the supernatant was 30% saturated with 
ammonium sulphate. After 4 h the homogenate 
was centrifuged for 20 min at 15 000 × g. The am- 
monium sulphate concentration i  the supernatant 
was increased to 70%. The precipitate was 
recovered, dissolved in 50 mM sodium acetate, pH 
5.0, and dialyzed against he same buffer. 
2.1.2. Chromatography on L-(+)-tartrate-AH- 
Sepharose 4B 
L-(+)-Tartrate was coupled to Sepharose 4B 
[15]. The dialyzed ammonium sulphate precipitate 
was applied to a 2.6 × 40 cm column of 
tartrate-AH-Sepharose, equilibrated with 50 mM 
Na-acetate, pH 5.0, at a flow rate of 38 ml/h. The 
column was washed with equilibration buffer until 
no protein could be recorded in the eluate (A2s0) 
and then eluted stepwise with equilibration buffer 
containing 10 and 25 mM L-(+)-tartrate. 
2.1.3. Chromatography on apoA-I-Sepharose 4B 
ApoA-I was coupled to CNBr-activated 
Sepharose 4B according to the instructions of 
Pharmacia Fine Chemicals (Sweden). Fractions 
eluted from the tartrate-AH-Sepharose column 
were pooled, neutralized with 1 M Tris and sub- 
jected to affinity chromatography on an apoA-I- 
Sepharose column (1.5 x 7 cm). The column was 
washed with PBS and then eluted with 0.1 M 
glycine, pH 2.0. 
2.1.4. Isolation of lipoproteins and apolipo- 
proteins 
Lipoproteins were isolated by ultracentrifuga- 
tion [16] and the apolipoproteins purified [171. 
2.2. Electrophoresis and ligand blotting 
After electrophoresis [18], the apoA-I-binding 
protein was transferred to 0.45/zm nitrocellulose 
membranes in 25 mM Tris/192 mM glycine/20% 
methanol (pH 8.3) for 1.5 h and 0.6 A. The mem- 
brane was then blocked, incubated overnight wi h 
3% gelatin in 10 mM Tris/saline, pH 7.4 (TBS), 
and thereafter incubated with purified apoA-I 
(10/zg/ml in TBS containing 1 °70 gelatin) for 8 h at 
room temperature. After washing twice for 20 rain 
with TBS containing 0.05% Tween incubation 
with a monoclonal apoA-I antibody (2AI), second 
antibody incubation and peroxidase staining were 
performed [19]. Coating of microtiter-plates with 
the apoA-I-binding protein was done as described 
[19], using a protein concentration of 5/zg/ml. 
2.3. Binding studies 
Purified apolipoproteins were diluted in 1%0 
gelatin/TBS (pH 7.4) to contain 0-50/zg/ml of 
protein and 100/zl of the dilutions were applied on 
microtiter plates coated with apoA-I BP. The 
plates were incubated for 2 h at room temperature 
and thereafter washed twice with 0.05% 
Tween/PBS. Then 100/zl of the respective an- 
tibodies, diluted in 1% gelatin/TBS (pH 7.4) were 
added to each well. The plates were incubated for 
1 h at room temperature and washed twice. The 
plates were treated with second antibodies (anti- 
mouse IgG and anti-rabbit IgG conjugated to 
alkaline phosphatase) and developed as in [19]. 
3. RESULTS 
3.1. Purification of apoA-l-binding protein 
To isolate the apoA-I-binding protein am- 
monium sulphate fractionation of the placental 
homogenate was performed following by affinity 
chromatography on AH-Sepharose 4B gels con- 
taining L-(+ )-tartrate. Fig. 1 illustrates the elution 
profile obtained after stepwise lution of the col- 
umn with 10 and 25 mM L-(+)-tartrate. The 
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Fig. 1. Affinity chromatography on L-(+ )-tartrate-AH- 
Sepharose 4B. The eluting buffers, 10 and 25 mM L- 
(+)-tartrate in 50 mM acetate buffer, pH 5.0, are 
indicated. (o-----o) Acid phosphatase activity as 
absorbance at 405 nm; (H)  absorbance at280 nm. 
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lysosomal acid phosphatase activity (LAP) eluted 
with l0 mM tartrate. Increasing the tartrate con- 
centration to 25 mM resulted in the elution of pro- 
tein but no further acid phosphatase activity. 
Affinity chromatography of the fractions with 
LAP activity on Sepharose gels containing im- 
mobilized apoA-I indicated that of the enzyme ac- 
tivity applied less than 1°70 was retained on the 
affinity matrix and 99°7o passed through the 
column. 
When the fractions eluting with 25 mM tartrate 
(fig.l) were combined and subjected to affinity 
chromatography on apoA-I-Sepharose apoA-I- 
binding protein could be recovered by eluting the 
column with 0.1 M glycine buffer (pH 2.0). 
3.2. Characterization o f  apoA-I-binding protein 
The affinity-purified apoA-I-binding protein 
(apoA-I-BP) was characterized by SDS gradient 
gel electrophoresis followed by ligand blotting 
(fig.2). The protein that elutes from the apoA-I af- 
finity column is a high-Mr protein or a protein ag- 
gregate as judged from SDS gel electrophoresis 
performed in the absence of reducing agents 
(fig.2B). This protein binds apoA-I as demon- 
strated by ligand blotting (fig.2A). Ligand blotting 
using apoA-II and the corresponding antibody did 
not result in any binding of apoA-II (not shown). 
When SDS gel electrophoresis was performed 
under reducing conditions two main bands, 50 and 
30 kDa, are evident (fig.2C) (Coomassie staining). 
Neither reacts with apoA-I in ligand blotting. 
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Fig.2. SDS gradient (5-20%) gel electrophoresis. Lanes: 
(A) ligand blotting of apoA-I-BP after SDS gel 
electrophoresis in the absence of reducing agent; (B-D) 
Coomassie blue-stained gels of: (B) apoA-I-BP, 10/~g 
applied in the absence of 2-mercaptoethanol; (C) the 
same amount of apoA-I-BP under educing conditions; 
(D) low molecular mass standards (Pharmacia) - (from 
the top) phosphorylase b (92.5 kDa), bovine serum 
albumin (66 kDa), ovalbumin (45 kDa), carbonic 
anhydrase (31 kDa), soybean trypsin inhibitor 
(21.5 kDa), lysozyme 04.4 kDa). 
Fig.3. Binding of purified apoA-I and apoA-I derived 
from plasma or HDL to immobilized apoA-I-BP. 
Microtiter plates coated with apoA-I-BP were incubated 
with different amounts of purified apoA-I (~---¢r), 
plasma (o ©) or isolated HDL (~. ~x) containing 
the indicated amounts of apoA-I as determined by 
immunoassay. After a 3 h incubation the wells were 
emptied, washed and the bound apoA-I visualized using 
monoclonal apoA-I antibody and enzyme labeled anti- 
mouse y-globulin antiserum. Control incubations in 
wells coated with bovine serum albumin showed no 
binding of apoA-I (= --). 
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To study further the binding properties of apoA- 
I-BP, it was immobilized on microtitration plates. 
Plates coated with different concentrations of 
apoA-I-BP bound increasing amounts of apoA-I 
in a saturable manner. However, when no apoA-I 
was added to the plates coated with apoA-I-BP no 
binding of the monoclonal A-I antibody could be 
observed indicating that the isolated apoA-I-BP 
preparation did not contain apoA-I. Also the 
apoA-I present in HDL or in serum showed 
saturable binding to the immobilized apoA-I-BP 
(fig.3). In experiments with apoA-I I ,  apoE and 
apoB (as LDL) only very low non-saturable 
binding could be demonstrated (not shown). To 
determine the specificity of the binding protein the 
binding of apoA-I (10/zg/ml) to microtitration 
wells coated with apoA-I-BP in the presence of in- 
creasing concentrations (10-100/zg/ml) of puri- 
fied apoproteins A-II, E and B (as LDL) was 
studied. These apoproteins did not compete for 
binding of apoA-I to the binding protein (not 
shown). Thus the binding protein we have purified 
appears to be specific for apoA-I. 
4. DISCUSSION 
The protein we have isolated from human 
placenta by affinity chromatography on L- (+)-  
tartrate-AH-Sepharose and immobilized apoA-I 
binds specifically the main apolipoprotein of 
HDL,  apoA-I. Why this protein also interacts with 
L-(+)-tartrate is not known at present. This latter 
interaction which has been considered rather 
specific for the tartrate-inhibitable lysosomal acid 
phosphatase (LAP) led us to believe that this en- 
zyme also binds the apolipoprotein A-I [14]. 
However, the present study clearly demonstrates 
that the LAP activity can be separated from the 
apoA-I-BP. In studies with microtiter plates 
coated with apoA-I or apoA-I-BP no binding of 
purified LAP to these proteins could be 
demonstrated (not shown), neither did the enzyme 
bind to apoA-I covalently linked to Sepharose. 
The presence of proteins involved in the binding 
of HDL to a number of different cell types has 
been demonstrated [10,11,20]. As HDL interacts 
differently with different cell types, delivers 
cholesterol to some and removes it from others, it 
is probable that the proteins mediating the 
lipoprotein-cell interaction are also different. 
Binding of HDL to human placental membrane 
fractions has been demonstrated [13], however, the 
binding site has not been isolated. The 
physiological function of the placental apoA-I-BP 
which we have isolated is not known and warrants 
further study. 
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